Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06494878
PHASE3

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Sponsor: University of Calgary

View on ClinicalTrials.gov

Summary

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Official title: The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8805

Start Date

2026-06-04

Completion Date

2030-12

Last Updated

2026-07-27

Healthy Volunteers

No

Interventions

DRUG

Aspirin

75-100 mg taken once daily by mouth.

DRUG

Low-molecular-weight heparin

Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Locations (12)

Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann

Brussels, Belgium

Foothills Medical Centre

Calgary, Alberta, Canada

The Ottawa Hospital - General Campus

Ottawa, Ontario, Canada

Hvidovre Hospital

Hvidovre, Capital Region, Denmark

CHU de Nancy

Nancy, France

APHP - Hôpital Port Royal

Paris, France

CHU de Saint-Etienne

Saint-Etienne, France

CHU de Toulouse

Toulouse, France

Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology

Dublin, Ireland

UCD Centre for Human Reproduction, The Coombe Hospital

Dublin, Ireland

Amsterdam UMC

Amsterdam, Netherlands

Medical University of Warsaw

Warsaw, Poland